← Human Trials & Peer-Reviewed Studies
Efficacy and Safety of Calcifediol in Young Adults with Vitamin D Deficiency: A Phase I, Multicentre, Clinical Trial-POSCAL Study.
Plain-language guide to PMID 38276544 (2024): double-blind randomized controlled trial of Vitamin D, K2, Magnesium and Zinc in 101 participants.
Key Facts
- PMID
- 38276544
- Journal
- Nutrients
- Year
- 2024
- Study type
- Randomized Controlled Trial
- Authors
- Guerra López P et al. (10 authors)
- DOI
- 10.3390/nu16020306
What This Study Did, in Plain Language
What Was Tested
The paper reports a study of Vitamin D, K2, Magnesium and Zinc, published as a randomized controlled trial.
Eighty-two percent of the subjects (79/96) achieved 25(OH)D levels within the target range (20-60 ng/mL) by the end of the TP, and they were subsequently randomised and subjected to a double-blind, placebo-controlled, five month follow-up phase (FP).
Who Took Part
The abstract describes 101 participants taking part.
By PubMed's age tags, the people studied were young adults and adults, both men and women.
How the Study Was Run
The design is described as randomized, double-blind, open-label, placebo-controlled and multicenter.
Random assignment meant chance, not the researchers, decided who got Vitamin D, K2, Magnesium and Zinc and who got the comparison, which limits bias.
As a double-blind Vitamin D, K2, Magnesium and Zinc study, the assignments were hidden from both participants and investigators until the end.
Nothing was hidden in this open-label Vitamin D, K2, Magnesium and Zinc study: the participants and staff both knew the treatment.
The comparison arm used a placebo, so changes seen with Vitamin D, K2, Magnesium and Zinc could be set against what happens without it.
What Was Measured
Eighty-two percent of the subjects (79/96) achieved 25(OH)D levels within the target range (20-60 ng/mL) by the end of the TP, and they were subsequently randomised and subjected to a double-blind, placebo-controlled, five month follow-up phase (FP).
PubMed files the paper under topics including Calcifediol, Vitamin D and Vitamin D Deficiency.
The authors tagged it with the keywords 25-hydroxyvitamin D3, clinical trial and young adults.
What This Means in Plain Language
The paper is a randomized, double-blind and open-label study of Vitamin D, K2, Magnesium and Zinc in 101 participants.
The publication is from 2024 (Nutrients), a journal based in Switzerland.
More context: the Vitamin D, K2, Magnesium and Zinc compound page, all human trials.
Our Notes on the Compound
Vitamin D, K2, Magnesium and Zinc: Magnesium is described as required for AMPK to function.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.